West High Yield (W.H.Y.) Resources Ltd. (TSXV: WHY) (FSE: W0H) (the ‘Company’ or ‘West High Yield’) announces the receipt of proceeds from the exercise...
Tech giant Nvidia (NASDAQ:NVDA) surpassed analyst expectations in both revenue and earnings per share in its recently released fiscal Q3 2025 results, driven by...
xReality Group Limited (ASX:XRG) (xReality) is pleased to present xReality Group Limited’s 2024 Annual General Meeting. 2024 Financial Performance In FY24 the company achieved...
xReality Group Limited (ASX:XRG) (xReality) is pleased to provide the following sales update for Operator XR, a wholly owned subsidiary of xReality Group Ltd....
Samarco Mineração, along with parent companies Vale (NYSE:VALE) and BHP (ASX:BHP,NYSE:BHP,LSE:BHP), has confirmed ongoing settlement negotiations with Brazilian authorities over the Fundão dam collapse....
Nordic Nickel Limited (ASX: NNL; Nordic, or the Company) is pleased to announce extremely positive results from its first pass metallurgical testing program for...
Hemlock Semiconductor (HSC) is set to enhance its operational capacity in Michigan, US, after the announcement of a preliminary agreement for a US$325 million...
IsoEnergy (TSX:ISO,OTCQX:ISENF) and Purepoint Uranium (TSXV:PTU,OTCQB:PTUUF) have formed a joint venture focused on the exploration and development of uranium properties in Saskatchewan’s Athabasca Basin....
IsoEnergy Ltd. (TSX: ISO) (OTCQX: ISENF) (‘IsoEnergy‘) and Purepoint Uranium Group Inc. (TSXV: PTU) (OTCQB: PTUUF) (‘Purepoint’) are pleased to announce that they have...
Lode Gold Resources Inc. (TSXV: LOD) (OTCQB: SBMIF) (‘Lode Gold ‘ or the ‘Company’) is pleased to announce its wholly-owned subsidiary, (‘1475039 B.C. Ltd.’...
Key Assay Highlights: Total Samples Analyzed: 388 rock samples. Titanium Dioxide (TiO2): 49 samples returned assay values over 4.0% TiO2, with a maximum value...
Quetzal Copper Corp. (TSXV: Q) (‘Quetzal’ or the ‘Company’) is pleased to announce the results from the Annual General Meeting (the ‘Meeting’) held on...
MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with...